Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZYMERGEN INC.

(ZY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Monday Deadline for Shareholders to Actively Participate in Zymergen, Inc. (ZY) Class Action: Bronstein, Gewirtz & Grossman, LLC

10/01/2021 | 11:02am EST

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zymergen, Inc. ("Zymergen” or the "Company") (NASDAQ: ZY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Zymergen common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's April 2021 initial public offering ("IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/zy.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that the Registration Statement was materially false and misleading and omitted to state material adverse facts, and that Defendants failed to disclose to investors that: (1) during the qualification process for Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/zy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Zymergen you have until October 4, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2021
All news about ZYMERGEN INC.
11/22INSIDER BUY : Zymergen
MT
11/15ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/11The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behal..
BU
11/10Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigati..
BU
11/03ZYMERGEN : Q3 Earnings Snapshot
AQ
11/03Zymergen Reports Preliminary Third Quarter 2021 Financial Results and Provides Business..
PU
11/03Earnings Flash (ZY) ZYMERGEN Reports Q3 Revenue $4.1M, vs. Street Est of $3.41M
MT
11/03Zymergen Reports Preliminary Third Quarter 2021 Financial Results and Provides Business..
AQ
10/26Zymergen to Report Third Quarter 2021 Financial Results on November 3, 2021
GL
10/21ZYMERGEN INC. : Entry into a Material Definitive Agreement, Costs Associated with Exit or ..
AQ
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2021 16,9 M - -
Net income 2021 -372 M - -
Net cash 2021 313 M - -
P/E ratio 2021 -1,97x
Yield 2021 -
Capitalization 928 M 928 M -
EV / Sales 2021 36,3x
EV / Sales 2022 50,5x
Nbr of Employees 758
Free-Float 90,7%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | ZY | US98985X1000 | MarketScreener
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 7
Last Close Price 9,06 $
Average target price 9,50 $
Spread / Average Target 4,86%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Jed Dean Vice President-Operations & Engineering
Aaron Kimball Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.0.00%972
SHIN-ETSU CHEMICAL CO., LTD.5.32%69 534
BASF SE-10.57%60 017
DUPONT DE NEMOURS, INC.4.01%39 915
ROYAL DSM N.V.36.22%36 863
PIDILITE INDUSTRIES LIMITED24.86%14 988